

**July 31, 2025**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Press Release – Q1 FY26**

---

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results for the quarter ended on June 30, 2025.

The above-mentioned Press Release is also being uploaded on the website of the company i.e. [www.mankindpharma.com](http://www.mankindpharma.com).

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**

**Company Secretary and Compliance Officer**

**Encl.: A/a**

**Press Release**

**Mankind Pharma revenue up by 24.5% with EBITDA margin 23.8% in Q1FY26.**

**New Delhi, India, 31 July, 2025:** Mankind Pharma (BSE: 543904 | NSE: MANKIND) India's fourth largest pharmaceutical Company today announced its financial results for the first quarter ended 30<sup>th</sup> June 2025. The information mentioned in this release is based on consolidated financial statements.

	Revenues	Dom. Revenue	EBITDA
	INR 3,570 Crore	INR 3,101 Crore	INR 850 Crore
<b>Q1 FY26</b>	<b>24.5% YoY ↑</b>	<b>18.9% YoY ↑</b>	<b>23.8% Margin</b>

**Mr. Rajeev Juneja – Vice Chairman & Managing Director**

“Mankind's revenue grew by 24.5% with EBITDA margins at 23.8% in Q1FY26 led by continued 1.4x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation.

Visible encouraging trends with 1.8x volume growth to IPM led by outperformance in Anti-infectives & Respiratory segment – apart from continued outperformance in Cardiology and Anti Diabetics.

BSV growth initiatives are making steady progress and we remain confident of delivering healthy performance this year onwards.

As we celebrate 30 years of our operations, we would like our shareholders to be part of this milestone therefore the Company's Board has approved an interim dividend of Rs 1 per share.”

**Q1 FY26 Performance Summary –**

- Revenue from Operations at INR 3,570 Cr, up by 24.5% YoY
  - Domestic revenue at INR 3,101 Cr, up 18.9%, Exports at INR 469 Cr, up 81.1% YoY
- EBITDA margin of 23.8% up by 20 bps YoY and PAT margin of 12.5%
- Diluted EPS<sup>1</sup> of INR 10.6 down by 20.1% YoY (FV Re.1)

1. Diluted EPS not annualised

## Press Release

### Domestic Business<sup>1</sup>

- Domestic revenue<sup>2</sup> increased by 18.9% YoY driven by steady growth in base business and BSV consolidation.
- Market share increased from 4.8% in Mar-25 to 4.9% as of Jun-25 on account of outperformance to IPM.
- Q1FY26 Secondary sales growth of 9.2% vs 8.6% IPM led by:
  - Healthy volume growth of 2.5% as compared to 1.4% IPM volume growth (1.8x outperformance).
  - Strong growth of 17.8% and 9.1% in respiratory and anti-infectives indicating an outperformance of 1.5x and 1.6x to IPM respectively.
  - Continued outperformance in chronic growth of 1.4x vs IPM chronic - 1.5x in Cardiac and 1.6x in Anti-Diabetics.
- Consistently maintained #1 rank over last 8 years with prescription share of 15.4%

1. As per IQVIA June-2025 || 2. Denotes reported number

### Consumer Healthcare Business<sup>1</sup>

- Strong revenue growth<sup>2</sup> of 15.0% YoY in Q1FY26 led by steady growth across all key brands
- MT & E-Com share increased to 11% in Q1FY26 as compared to 9% in Q1FY25 supported by ~50% growth
- Strong growth in secondary sales for Gas-o-fast, Manforce Condom, HealthOk, and Peganews of 36%, 18%, 15%, and 12% YoY respectively in Q1FY26
- Gaining strong traction with launches in Epic ThinX (Unflavored premium category condom), Nimulid (Pain Management) and OvaNews (Ovulation Detection Kit)

1. As per IQVIA / IQVIA Retail June-2025 || 2. Denotes reported number

### Exports

- Revenue growth of 81.1% YoY primarily due to consolidation of BSV supported by growth in base business
- Mankind (excl. BSV) has launched 1 product in Q1FY26; taking the total launched products to 45 in US

## Press Release

### Consolidated Profit & Loss Account

In INR Crore	Q1 FY26	Q1 FY25	YoY%	Q4 FY25	QoQ%
Revenue from Operations	3,570	2,868	24.5%	3,079	15.9%
<i>Gross Margins %</i>	<i>70.5%</i>	<i>71.8%</i>	<i>(130 bps)</i>	<i>71.6%</i>	<i>(110 bps)</i>
EBITDA	850	675	25.8%	686	24.0%
<i>EBITDA Margin %</i>	<i>23.8%</i>	<i>23.6%</i>	<i>20 bps</i>	<i>22.3%</i>	<i>150 bps</i>
PAT	445	538	(17.4%)	429	3.6%
<i>PAT Margin %</i>	<i>12.5%</i>	<i>18.8%</i>	<i>(630 bps)</i>	<i>13.9%</i>	<i>(140 bps)</i>
Diluted EPS (INR) <sup>1</sup>	10.6	13.3	(20.1%)	10.3	3.0%
Cash EPS (INR) <sup>1</sup>	15.9	15.8	0.5%	15.9	0.1%

1. Diluted EPS and Cash EPS not annualised

### Segmental Revenue Break Up

In INR Crore	Q1 FY26	Q1 FY25	YoY%	Q4 FY25	QoQ%
Domestic	3,101	2,609	18.9%	2,544	21.9%
• <i>Consumer Healthcare</i>	<i>237</i>	<i>206</i>	<i>15.0%</i>	<i>178</i>	<i>33.1%</i>
Exports	469	259	81.1%	535	(12.3%)
<b>Total</b>	<b>3,570</b>	<b>2,868</b>	<b>24.5%</b>	<b>3,079</b>	<b>15.9%</b>

### Earning Concall Details

Date	01 <sup>st</sup> August, 2025
Time	12:00 pm – 01:00 pm IST
Universal Access Numbers	+91-22-6280 1102 / +91-22-7115 8003
Diamond Pass	<a href="#">Click here</a>

## Press Release

### About Mankind Pharma

**Mankind Pharma (BSE: 543904 | NSE: MANKIND)** is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women's health segment. Mankind's distribution network includes a robust field force of ~18,000 professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 30 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 770+ scientists. For more information, visit [www.mankindpharma.com](http://www.mankindpharma.com)

### Safe Harbour Statement

The statements, are as on date and may contain forward-looking statements like the words "believe", "expects", "anticipate", "aim", "will likely result", "Would", "will continue", "contemplate" "intends", "plans", "estimates", "seek to", "future", "objective", "projects", "goal", "likely", "Project", "should", "potential" "will", "may", "targeting" or other words of similar expressions/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward-looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance.

The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, Company assume no responsibility to publicly amend, modify or

**Press Release**

revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise.

**For Queries Contact**

**Investor Relations**

Abhishek Agarwal

Email address: [investors@mankindpharma.com](mailto:investors@mankindpharma.com)

Contact Number: +91-11-46846700

**Corporate Communication**

Natasha Raj

Email address: [natasha.raj@mankindpharma.com](mailto:natasha.raj@mankindpharma.com)

Contact Number: 011-46846700 Ext: 3201

**Investor Relations / Public Relations**

Smit Shah / Apoorva Sharma

Email address: [smit.shah@adfactorspr.com](mailto:smit.shah@adfactorspr.com) / [apoorva.sharma@adfactorspr.com](mailto:apoorva.sharma@adfactorspr.com)

Contact Number: +91 9870789596 / +91 9999739452